

Thrombus in transit through a patent foramen ovale: catch it if you can—a case report

Maria Inês Fiuza Branco Pires (1) *, Inês Almeida (1) , João Miguel Santos (1) , and Miguel Correia (1)

Cardiology Department, Tondela-Viseu Hospital Centre, Avenida Rei D. Duarte, 3504-509 Viseu, Portugal

Received 13 March 2021; first decision 16 April 2021; accepted 14 September 2021; online publish-ahead-of-print 1 October 2021

Background	Patent foramen ovale (PFO) is one of the most common congenital heart defects, but the finding of a thrombus in transit (TIT) through a PFO is extremely rare. It is a therapeutic challenge, and systemic anticoagulation, cardiac surgery, or fibrinolysis should be considered.
Case summary	A 43-year-old woman was admitted with intermediate-high-risk pulmonary embolism. Transthoracic echocardio- gram revealed a large right atrial mobile mass that crossed the interatrial septum through a PFO, compatible with TIT, and the patient was started on unfractionated heparin. The diagnosis was confirmed by transoesophageal echocardiogram (TOE). However, during TOE probe removal, the patient developed dyspnoea, sudoresis, and per- ipheral desaturation, and new image acquisition revealed sudden mass disappearance. Due to the possibility of para- doxical embolization associated with Valsalva manoeuvre, fibrinolysis with alteplase was promptly started. The pa- tient had no signs of embolic or haemorrhagic complications and remained clinically stable. She was discharged on warfarin and then underwent percutaneous transcatheter closure of PFO.
Discussion	The treatment strategy of a TIT through a PFO is controversial, but surgery might be the most appropriate treat- ment for haemodynamically stable patients, while thrombolysis should be used in cases of haemodynamic instability. Transoesophageal echocardiogram is generally a safe procedure but pressure changes associated with Valsalva man- oeuvre may induce embolization of a TIT and attention should be given to patient sedation and tolerance. After complete embolization of a TIT, emergent thrombolysis may be the only treatment option, in order to prevent dis- astrous consequences related to paradoxical embolism.
Keywords	Thrombus in transit • Patent foramen ovale • Fibrinolysis • Pulmonary embolism • Case report

Learning points

- The finding of a thrombus in transit (TIT) through a patent foramen ovale (PFO) is extremely rare, and its treatment may include anticoagulation, fibrinolysis, or cardiac surgery.
- Transoesophageal echocardiogram is generally a safe procedure but pressure changes associated with Valsalva manoeuvre may induce embolization of a TIT.
- After spontaneous and complete embolization of a TIT, fibrinolysis may be the only treatment option, and PFO closure is recommended to prevent new episodes of systemic embolization.

* Corresponding author. Tel: +35 191 827 0092, Email: inesfbpires@gmail.com

Handling Editor: Mohammed Al-Hiji

Peer-reviewers: Flemming Javier Olsen and Luis Antonio Moreno-Ruiz

Compliance Editor: Edwina McNaughton

Supplementary Material Editor: Elhosseyn Guella

[©] The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Patent foramen ovale (PFO) is a congenital heart defect that affects 20–34% of the population.¹ Most patients are asymptomatic but some may suffer from paradoxical embolization. Diagnosis of paradoxical embolization associated with PFO is generally presumptive, as the finding of a thrombus in transit (TIT) through a PFO is extremely rare. In this situation, the treatment is controversial and may include anticoagulation, fibrinolysis or cardiac surgery, or a combination of these.²

We present a case of pulmonary embolism with a thrombus crossing a PFO with paradoxical embolization induced by Valsalva manoeuvre during transoesophageal echocardiogram (TOE), and discuss treatment options.

Timeline

Time	Event
2 days before admission	Symptom onset (chest pain and dyspnoea)
Admission (Day 0)	Diagnosis of pulmonary embolism
Day 1	Spontaneous embolization of thrombus in
	transit through the patent foramen ovale
	(PFO) during transoesophageal echocar-
	diogram. Fibrinolysis.
Day 20	Hospital discharge (on warfarin)
6 months	PFO closure
12 months	Switch from warfarin to apixaban
24 months	Follow-up without new embolic episodes

Case presentation

A 43-year-old Caucasian female was admitted to the emergency department with chest pain and dyspnoea that persisted for 2 days. She had history of erythema nodosum, thyroid nodules, and leg varicose veins treated with sclerotherapy in the previous month, and was medicated with a combined oral contraceptive (drospirenone/ethinyl estradiol 3 mg/0.03 mg). There was no history of smoking, trauma or immobilization, or relevant family history.

Physical examination revealed tachycardia (104 b.p.m.), normal blood pressure (135/89 mmHg), oxygen saturation of 98% on room air. The patient was eupneic, cardiopulmonary auscultation was unremarkable and there were no signs of peripheral hypoperfusion or deep venous thrombosis. Arterial blood gas analysis showed respiratory alkalaemia with normal lactate levels. Electrocardiogram revealed sinus tachycardia with T-wave inversion in right precordial leads and the chest X-ray was unremarkable. Laboratorial evaluation showed D-dimers of 11014 ng/mL (normal <250) and troponin I of 0.24 ng/mL (normal <0.06). Chest computed tomography (CT) angiography identified extensive bilateral pulmonary embolism, and right atrial (RA), right ventricular (RV), and pulmonary trunk enlargement (*Figure 1*).

The patient was admitted to the cardiac intensive care unit due to unprovoked intermediate-high-risk pulmonary embolism. A bedside transthoracic echocardiogram (TTE) revealed signs of RV pressure overload, with right chambers dilation, flattened interventricular septum, RV-RA pressure gradient of 50 mmHg, tricuspid annular planar systolic excursion of 16 mm, and a RA mobile mass, suggestive of a thrombus, that apparently crossed the interatrial septum through a PFO (*Figure 2* or *Video 1*). Anticoagulation, fibrinolysis, or cardiac surgery were considered but, due to the haemodynamic stability, unfractionated heparin was started.

After discussion with cardiothoracic surgery, a TOE was performed, under sedation with midazolam, revealing a big mobile filiform mass with ~60 mm, located in the RA and crossing the interatrial septum through a PFO, with extension to the left atrium and mitral valve, suggestive of a TIT (*Figure 3* or *Video 2*). During probe removal, the patient developed dyspnoea, sudoresis, and peripheral desaturation. TOE probe was reintroduced and the mass had disappeared (*Figure 4*). Both pulmonary embolism and paradoxical embolization were suspected, as there was peripheral desaturation and the mass had a significant extension to the left cardiac chambers.

Even though the patient was haemodynamically stable, without neurological deficits and stabilized with supplemental oxygen via Venturi mask at 28%, fibrinolysis with alteplase was promptly started, due to the possibility of paradoxical embolization. There were no clinically evident haemorrhagic or embolic complications. The patient developed drowsiness and vomiting but remained stable and the neurological examination and the cranioencephalic CT were normal.

Over the next days, the patient remained stable. Repeated TTE revealed normalization of right cardiac chambers dimensions and function. An exhaustive evaluation to exclude secondary causes of pulmonary embolism identified homozygosity for the 4G polymorphism of the plasminogen activator inhibitor 1 gene. Thoraco-abdom-ino-pelvic CT identified right common carotid artery thrombosis, involving external and internal branches.

The patient was discharged on warfarin to a target international normalized ratio (INR) of 2 to3, and the oral contraceptive was stopped.

Six months after discharge, the patient was referred for percutaneous transcatheter closure of PFO, and started a 1-month course of clopidogrel, while maintaining warfarin. Twelve months after discharge, a genetic thrombophilia screen was repeated and excluded thrombophilic disorders. After discussion with immunohematologyand internal medicine, as this was the first episode of unprovoked pulmonary embolism, switch to lifelong oral anticoagulation with apixaban 2.5 mg bid was decided. After 24 months of follow-up, the patient is asymptomatic, without further evidence of pulmonary or systemic embolization.

Discussion

We present a rare case of a TIT through a PFO, treated with fibrinolysis after embolization induced by Valsalva manoeuvre during TOE.

PFO results from incomplete fusion of septum primum and septum secundum that generally occurs after birth.³ In the majority of time, PFO is functionally closed, but it can be opened by manoeuvres



Figure I Chest computed tomography angiography showing bilateral pulmonary embolism (arrows) and right chamber (asterisk) and pulmonary trunk (arrowhead) enlargement.




Figure 2 Bedside transthoracic echocardiogram showing right chambers dilation (asterisk), flattened interventricular septum (arrowhead), a right atrial mobile mass that apparently crossed the interatrial septum (arrow), and right ventricular–right atrial pressure gradient of 50 mmHg.



Video I Apical four-chamber view showing a right atrial mobile mass that apparently crossed the interatrial septum, right chambers dilation and flattened interventricular septum.

that change intrathoracic pressure, allowing interatrial passage of substances.¹ Therefore, although most patients with PFO are asymptomatic, others may suffer from paradoxical embolization.⁴

The incidence of paradoxical embolism associated with PFO is difficult to establish, because the diagnosis is usually presumptive and based on the concomitant presence of venous thromboembolic disease, arterial embolism, and a PFO. The finding of a TIT through a PFO is extremely rare.⁵ The first case diagnosed by TOE was reported in 1985 by Nellessen *et al.* and the most recent literature review included 194 patients, from 1991 to 2015.^{6,7}

Treatment of a TIT is controversial due to the lack of prospective randomized trials, but a cardiothoracic surgeon should be consulted after diagnosis.^{2,8}

Emergent thoracotomy with thrombectomy and surgical PFO closure may be the best option for haemodynamically stable patients, as studies have shown a lower incidence of post-treatment embolic events and mortality.^{47,9}



Figure 3 Mid-oesophageal basal short-axis view showing a big mobile filiform mass (arrow) located in the right atrium and crossing the interatrial septum through a patent foramen ovale, with extension to the left atrium and mitral valve.



Figure 4 Mid-oesophageal basal short-axis view (the same view as Figure 3) after sudden mass disappearance.



Video 2 Mid-oesophageal basal short-axis view showing a big mobile filiform mass located in the right atrium and crossing the interatrial septum through a patent foramen ovale, with extension to the left atrium and mitral valve.

Anticoagulation alone is primarily used in patients with important comorbidities, high surgical risk, or when patients refuse invasive therapy.^{7,10}

Fibrinolysis is generally reserved for poor surgical candidates, haemodynamically unstable patients with high-risk pulmonary embolism or for cases of acute ischaemic stroke, as it may cause thrombus fragmentation and/or embolization and is associated with higher mortality.^{7,11}

To our knowledge, there is only one published case of a TIT through a PFO that embolized during TOE, after the patient coughed.² Although TOE is associated with a low complication rate, oesophageal intubation can induce vagal and sympathetic reflexes, with blood pressure and heart rate fluctuations. Besides that, even

after sedation and local anaesthesia of the pharynx, retching and coughing commonly occur, and the associated Valsalva manoeuvre induces changes in intrathoracic, central venous, and pulmonary pressures. These pressure variations may cause the mobilization of any intracardiac material, with subsequent pulmonary or systemic embolization. The extent of embolization will depend on the haemodynamic fluctuations associated with Valsalva manoeuvre as well as on mass characteristics, such as size, density, and mobility. In order to prevent embolization, sedation is very important to improve patient tolerance and under general anaesthesia retching and gag reflex are abolished.¹²

After embolization of a TIT through a PFO, emergent thrombolysis may be indicated due to the very high risk of paradoxical embolization with potential serious consequences.²

Regarding oral anticoagulation after surgery or fibrinolysis, most authors chose vitamin K antagonists with a target INR 2–3. We found one report of the use of apixaban 5 mg twice a day after surgical thrombectomy¹³ and another of dabigatran after thrombolysis.⁷ Nevertheless, the possible role of direct oral anticoagulants still remains undefined.¹³

Most paradoxical embolisms present as cerebrovascular events, given the anatomy of the aortic arch.¹ Decision about PFO closure should be based on the probability that the foramen ovale has a relevant role in the observed clinical scenario and the likelihood of recurrence.¹⁴ In this case, the finding of a TIT and, after its embolization, of right common carotid artery thrombosis proves paradoxical embolization and is an indication for treatment.

In conclusion, this case reflects the therapeutic challenge of a TIT through a PFO. Although TOE is generally safe, pressure changes associated with Valsalva manoeuvre may induce embolization of a TIT, and careful consideration should be given to patient sedation and tolerance in order to prevent triggering this manoeuvre. After embolization of a TIT, fibrinolysis can be the only treatment option, in order to prevent disastrous consequences related to paradoxical embolism.

Lead author biography



Maria Inês Pires is a Cardiology resident in the Tondela-Viseu Hospital Centre, with interest in Heart Failure. She is graduated from the School of Health Sciences, University of Minho.

Supplementary material

Supplementary material is available at European Heart Journal - Case Reports online.

Slide sets: A fully edited slide set detailing this case and suitable for local presentation is available online as Supplementary data.

Consent: The author/s confirm that written consent for submission and publication of this case report including images and associated text has been obtained from the patient in line with COPE guidance.

Conflict of interest: None declared.

Funding: None declared.

References

- Giblett JP, Abdul-Samad O, Shapiro LM, Rana BS, Calvert PA. Patent foramen ovale closure in 2019. Interv Cardiol 2019;14:34–41.
- Kim JH, Kim YJ. Thrombus in transit within a patent foramen ovale: gone with the cough! J Cardiovasc Ultrasound 2011;19:196–198.
- Abdelghani M, El-Shedoudy SAO, Nassif M, Bouma BJ, de Winter RJ. Management of patients with patent foramen ovale and cryptogenic stroke: an update. *Cardiology* 2019;**143**:62–72.
- Ibebuogu UZ, Khouzam RN, Sharma G, Thornton JW, Robati R, Silverman D. A thrombus in transit through a patent foramen ovale. JAAPA 2014;27:32–35.
- Leach JR, Elicker B, Yee J, Puppula S, Wisneski JA, Yeh BM. Clot through the heart: paradoxical embolism with thrombus-in-transit at multidetector computed tomography. J Comput Assist Tomogr 2015;39:598–600.
- Nellessen U, Daniel WG, Matheis G, Oelert H, Depping K, Lichtlen PR. Impending paradoxical embolism from atrial thrombus: correct diagnosis by transesophageal echocardiography and prevention by surgery. J Am Coll Cardiol 1985;5:1002–1004.
- Seo WW, Kim SE, Park MS, Lee JH, Park DG, Han KR et al. Systematic review of treatment for trapped thrombus in patent foramen ovale. *Korean Circ J* 2017;47:776–785.
- Bakhshi H, Meyghani Z, Shakir Z, Chen A, Kershner D. Thrombus entrapped in patent foramen ovale: a rare form of thrombus in transit. J Community Hosp Intern Med Perspect 2015;5:28170.
- Myers PO, Bounameaux H, Panos A, Lerch R, Kalangos A. Impending paradoxical embolism. Systematic review of prognostic factors and treatment. *Chest* 2010; 137:164–170.
- Baydoun H, Barakat I, Hatem E, Chalhoub M, Mroueh A. Thrombus in transit through patent foramen ovale. *Case Rep Cardiol* 2013;2013:395879.
- Fauveau E, Cohen A, Bonnet N, Gacem K, Lardoux H. Surgical or medical treatment for thrombus straddling the patent foramen ovale: impending paradoxical embolism? Report of four clinical cases and literature review. *Arch Cardiovasc Dis* 2008;**101**:637–644.
- Côté G, Denault A. Transesophageal echocardiography-related complications. Can J Anaesth 2008;55:622–647.
- Ieva R, Magnesa M, Gallo N, Cassese M, Di Biase M, Brunetti ND. Pulmonary embolism and thrombus in transit through patent foramen ovale. *Ann Vasc Surg* 2020;63:457.e19–457.e21.
- Pristipino C, Sievert H, D'Ascenzo F, Louis Mas J, Meier B, Scacciatella P et al.; International Experts. European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. *Eur Heart J* 2019;40:3182–3195.